Company Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Ram Aiyar |
Contact Details
Address: 60 First Street, 2nd Floor Cambridge, Massachusetts 02141 United States | |
| Phone | 617 468 1999 |
| Website | korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer and Director |
| Dr. Loic Vincent Ph.D. | Chief Scientific Officer |
| Dr. Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Andrew Fraley Ph.D. | Co-Founder and Advisor |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder and Advisor |
| Todd Chappell M.B.A. | Chief Operating Officer |
| Oliver Dolan | Senior Vice President of Finance and Principal Accounting Officer |
| Stephanie Engels | Chief People Officer |
| Dr. Gaozhong Zhu Ph.D. | SVice President of Chemistry, Manufacturing and Controls and Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2026 | SCHEDULE 13G/A | Filing |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | EFFECT | Notice of Effectiveness |
| Mar 20, 2026 | 424B5 | Filing |
| Mar 17, 2026 | SCHEDULE 13G | Filing |
| Mar 13, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 12, 2026 | SCHEDULE 13D/A | Filing |